Clinical Study

Bn42083 A Phase IIIb Multicenter, Randomized, Double-Blind, Controlled Study To Evaluate The Efficacy, Safety And Pharmacokinetics Of A Higher Dose Of Ocrelizumab In Adults With Primary Progressive Multiple Sclerosis

Posted Date: Feb 15, 2021

  • Investigator: Aram Zabeti
  • Specialties: Multiple Sclerosis, Neurology
  • Type of Study: Drug

The primary efficacy objective is to demonstrate the superiority of a higher dose of ocrelizumab over the approved dose of ocrelizumab as assessed by risk reduction in cCDP sustained for at least 12 weeks.


Participant Must Be Between 18-55 That Has Been Diagnosed With Primary Progressive Multiple Sclerosis (Ppms) And Be Neurologically Stable For At Least 30 Days Prior To Randomization And Baseline Assessments.


Primary Progressive Multiple Sclerosis, Neurology, Ocrelizumab

For More Information:

Tiffany Rupert

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.